Candel Therapeutics Inc

Market Cap

$596M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$9.64+$4.20 (+77.21%)

Jul 15, 2026

52W High $10.3652W Low $4.42

Company Details

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical tria...

Leadership

Paul-Peter Tak FOCIS, M.D., Ph.D.

President, CEO & Director

Charles Schoch

Senior VP, CFO, Treasurer & Secretary

Francesca Barone M.D., Ph.D.

Chief Scientific Officer

Seshu Tyagarajan Ph.D.

Chief Technical & Development Officer

Ileen B. Winick

Chief People Officer

Susan Stewart J.D., L.L.M.

Chief Regulatory Officer

William Nichols Garrett M.D., M.S.

Chief Medical Officer

IPO Date

Jul 27, 2021

Website

www.candeltx.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$54M

EPS (Diluted)

Free Cash Flow

-$49M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee